Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the
urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided …

Background Sacituzumab govitecan (SG) is a Trop-2-directed antibody–drug conjugate
containing cytotoxic SN-38, the active metabolite of irinotecan. SG received accelerated US …

The FGFR signaling pathway is integral to cellular activities, including proliferation,
differentiation, and survival. Dysregulation of this pathway is implicated in numerous human …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

Urothelial carcinoma (UC) is a common cancer associated with a poor prognosis in patients
with advanced disease. Platinum-based chemotherapy has remained the cornerstone of …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …

The regulation of immunosuppressive microenvironments in tumors through targeted drug
delivery shows promise for immunochemotherapy in bladder cancer. Drawing inspiration …

Cisplatin-based chemotherapy is currently the first-line standard of care for patients with
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for …